License agreement on LPA1 antagonistMarch 27, 2018
Ube Industries, Ltd.
Curadim Pharma Co., Ltd.
Ube Industries and Curadim Pharma sign license agreement on LPA1 antagonist
TOKYO, March 27, 2018: Ube Industries, Ltd. and Curadim Pharma Co., Ltd. announced today that they have entered into a license agreement regarding Ube Industries’ lysophosphatidic acid receptor 1 (LPA1) selective antagonist (development code: CP2090; hereinafter the “compound”).
Under the agreement, Curadim Pharma acquires the right to develop, manufacture, and market the compound and formulations using the compound worldwide. Ube Industries reserves the right to develop, manufacture, and market the compound’s active pharmaceutical ingredient.